Cognitive Behavioral Therapy (CBT) for Tinnitus: What Does the Evidence Show?

Cognitive behavioural therapy for tinnitus (Cochrane Review)

Fuller T, Cima R, Langguth B, Mazurek B, Vlaeyen JWS, Hoare DJ · Cochrane Database of Systematic Reviews · 2020 · N=2,733 (28 studies) · Systematic review of RCTs

CBT vs no treatment: SMD −0.56 (95% CI −0.83 to −0.30; ≈10.9 THI points lower; 10 studies, 537 participants; low certainty). CBT vs audiological care: THI −5.65 points (95% CI −9.79 to −1.50; 3 studies, 444 participants; moderate certainty). CBT vs TRT: −15.79 points (95% CI −27.91 to −3.67; ONE study of 42 participants; low certainty). Essentially no reported harms.

Also reduced depression (SMD −0.34) and anxiety (SMD −0.45, very low certainty). Only weak, if any, effects on perceived loudness.

PubMed 31912887 · DOI 10.1002/14651858.CD012614.pub2

UNITI-RCT: single versus combined treatments for chronic tinnitus

Schoisswohl S, Basso L, Simoes J, et al. (incl. Langguth B) · Nature Communications · 2025 · N=461 (230 single / 231 combination) · Multicenter RCT, 5 sites in 4 countries

Within-group THI change: −11.7 (single treatments) vs −14.9 (combinations); the between-group difference of ≈3.2 points was statistically significant (p=0.034) but below a ~7-point clinical-meaningfulness benchmark (external literature value — the paper itself does not define this threshold). Paper verbatim: CBT and hearing aids alone had large effect sizes 'which could not be further increased by combination treatment.'

The largest trial ever to compare tinnitus treatments head-to-head. Statistically significant, clinically marginal difference between strategies — the substantive finding is which single treatments performed best.

PubMed 41271763 · DOI 10.1038/s41467-025-66165-1

Internet-based audiologist-guided CBT for tinnitus: US randomized controlled trial

Beukes EW, et al. · Journal of Medical Internet Research · 2022 · N=158 (79 iCBT / 79 monitoring) · RCT

Post-treatment TFI 36.6 vs 46.3 (Cohen d = 0.46). Clinically significant improvement in 57% vs 15% — by the paper's own reliable-change criterion, not the standard 13-point TFI threshold.

Control was weekly monitoring (no active comparator). 1-year follow-up paper reported maintained efficacy (PMID 36353148).

PubMed 35156936 · DOI 10.2196/27584

Tinnitus — current developments (state-of-the-field overview)

Mazurek B, Steinmetzger K, Boecking B, Hesse G, Brueggemann P. · HNO · 2025 · N=— · Narrative review

CBT 'remains the gold standard.' Neuromodulation's clinical effectiveness judged 'relatively low'; for bimodal tongue stimulation, significant effects only in moderate-severe tinnitus and 'proof of clinical relevance is still lacking.'

PubMed 40920197 · DOI 10.1007/s00106-025-01668-3

Specialised CBT-based stepped care vs usual care (largest CBT trial)

Cima RFF, Maes IH, Joore MA, et al. · The Lancet · 2012 · N=492 randomized (245 specialised / 247 usual care) · RCT, assessor-masked; stepped multidisciplinary CBT-based care vs usual care; NCT00733044

All three primary outcomes favored specialised care over 12 months: HUI +0.059 [0.025, 0.094] (d=0.24, p=0.0009); TQ −8.06 [−10.83, −5.30] (d=0.43, p<0.0001); THI −7.51 [−10.66, −4.35] (d=0.45, p<0.0001). Effective across severity strata; no adverse events.

The foundational trial behind guideline recommendations for CBT-based tinnitus care. Distress/QoL outcomes — no loudness endpoint. Funded by ZonMW (Netherlands).

PubMed 22633033 · DOI 10.1016/S0140-6736(12)60469-3

AAO-HNSF Clinical Practice Guideline: Tinnitus

Tunkel DE, Bauer CA, Sun GH, et al. · Otolaryngology–Head and Neck Surgery · 2014 · N=Guideline (23-author multidisciplinary panel) · Clinical practice guideline (US)

RECOMMENDS: hearing-aid evaluation (with hearing loss) and CBT for persistent bothersome tinnitus. OPTION: sound therapy ('may recommend'). AGAINST routine use: medical therapy (antidepressants, anticonvulsants, anxiolytics, intratympanic drugs), dietary supplements (Ginkgo, melatonin, zinc), and rTMS. NO RECOMMENDATION: acupuncture.

Guidelines are consensus documents, not new trial data. Where the three major guidelines disagree — chiefly on sound therapy (AAO-HNSF: option; NICE and the European guideline: research-only; the German S3 guideline: against sound generators) — this platform shows the disagreement rather than picking a side. Statement strengths read from the published abstracts; full-text verbatim wording not independently re-read.

PubMed 25273878 · DOI 10.1177/0194599814545325

NICE guideline NG155: Tinnitus — assessment and management

National Institute for Health and Care Excellence · NICE (UK) · 2020 · N=National guideline · Clinical practice guideline (UK)

Amplification: OFFER with hearing loss affecting communication; CONSIDER with hearing loss without communication difficulty; DO NOT OFFER without hearing loss. Psychological therapies (stepped): digital tinnitus-related CBT → group interventions (MBCT/ACT/CBT) → individual CBT. Betahistine: 'Do not offer betahistine to treat tinnitus.' Sound therapy and neuromodulation: 'We were unable to make recommendations for practice in this area.'

Also advises against psychoacoustic pitch/loudness matching for assessment. Read from the official NICE pathway document (NBK557037 mirror). NICE's sound-therapy position (no practice recommendation) conflicts with AAO-HNSF's 'option' — shown as a disagreement, not resolved by this platform.

PubMed 32437098

European multidisciplinary guideline for tinnitus

Cima RFF, Mazurek B, Haider H, et al. · HNO · 2019 · N=Multinational guideline · Clinical practice guideline (Europe)

CBT: STRONG recommendation FOR. Hearing aids: FOR, with hearing loss. Sound therapy: recommendation for RESEARCH only (no practice recommendation — not an 'against'). Pharmacotherapy: weak recommendation AGAINST. Transcranial electrical stimulation: AGAINST.

Stances verified via a peer-reviewed secondary source (Langguth et al., J Clin Med 2023, PMC10178961) because the primary full text is paywalled; verbatim wording and grading system therefore marked unable-to-verify. Together with AAO-HNSF 2014 and NICE NG155, the three guidelines agree on CBT (for) and drugs (against) and diverge on sound therapy.

PubMed 30847513 · DOI 10.1007/s00106-019-0633-7

CBT for hyperacusis: randomized controlled trial (adjacent evidence)

Jüris L, et al. · Behaviour Research and Therapy · 2014 · N=60 · RCT: CBT vs waitlist for hyperacusis

Significant benefits favoring CBT with moderate-to-large effects (d≈0.67–0.69 on loudness discomfort levels), maintained at 12 months. ADJACENT evidence: hyperacusis, not tinnitus — included because the conditions overlap heavily.

PubMed 24508581 · DOI 10.1016/j.brat.2014.01.001